Drugs / CFI-402411
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04521413 | Aug 2020 → Nov 2025 overdue | high grade malignant neoplasm | Treadwell Therapeutics, Inc | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CFI-402411 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04521413 ↗ |
| Action | Inhibit | “CFI-402411 is an oral pill that blocks the function of HPK1.” NCT04521413 ↗ |
| Route | Oral | “CFI-402411 is administered orally once daily.” NCT04521413 ↗ |